{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:31:21Z","timestamp":1790688681387,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2006,6,12]],"date-time":"2006-06-12T00:00:00Z","timestamp":1150070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To demonstrate a linkage methodology for mother and baby automated medical records, and describe frequency, type, and pregnancy risk level of medications prescribed during pregnancy in a GPRD cohort, 1991\u20131999.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We linked records using a two\u2010stage algorithm and selected pairs with \u22657 months prenatal records and \u22652 records in baby's first year of life. Periods of interest were: 90 days prior to a woman's earliest identified pregnancy record (Period I), and this record plus 70 days (Period II, approximate early pregnancy). Medications were classified using the British National Formulary and US Food and Drug Administration Pregnancy Risk Categories.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We achieved over 80% record linkage and defined a cohort of 81\u2009975. Sixty\u2010five per\u2009cent of mothers had \u22651 prescription during both periods combined. Most frequent medications in Period I were anti\u2010bacterial, contraceptive, topical steroid, and bronchodilator. In Period II, they were folic acid, anti\u2010bacterial, antacid, and gynecological anti\u2010infective. In Period I, 4% were FDA category A (considered safest), 34% B, and 49% C and D combined. By Period II, prescription of category A medications increased (folic acid, iron) while other categories declined. Category X medications, with potential teratogenic risk that outweighs maternal benefit, were prescribed to 5714 (7%) women in Period I, and 501 (0.6%) women in Period II (46% progesterone).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>One in every 164 women received a category X prescription in early pregnancy. The visit when pregnancy is first medically recognized represents an opportunity to review prescribed medications in light of contraindication and\/or fetal risk. Copyright \u00a9 2006 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1269","type":"journal-article","created":{"date-parts":[[2006,6,12]],"date-time":"2006-06-12T11:32:10Z","timestamp":1150111930000},"page":"555-564","source":"Crossref","is-referenced-by-count":77,"title":["Safety of medications prescribed before and during early pregnancy in a cohort of 81\u2009975 mothers from the UK General Practice Research Database"],"prefix":"10.1002","volume":"15","author":[{"given":"Janet R.","family":"Hardy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Leaderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore R.","family":"Holford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian C.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Bracken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,6,12]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.9.824"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2005.14.104"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427060-00001"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804163381607"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.125740"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7171.1503"},{"key":"e_1_2_1_8_2","volume-title":"Human Malformations and Related Anomalies","author":"Stevenson RE","year":"1993"},{"key":"e_1_2_1_9_2","first-page":"423","volume-title":"Perinatal Epidemiology","author":"Bracken MB","year":"1984"},{"key":"e_1_2_1_10_2","first-page":"1","volume-title":"Key health statistics from General Practice 1998: analyses of morbidity and treatment data, including time trends, England and Wales","author":"Office for National Statistics","year":"1998"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.608"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/91.6.445"},{"key":"e_1_2_1_13_2","first-page":"36","article-title":"The General Practice Research Database: quality of morbidity data","volume":"87","author":"Hollowell J","year":"1997","journal-title":"Popul Trends"},{"key":"e_1_2_1_14_2","first-page":"1","volume-title":"The General Practice Research Database: information for researchers","author":"Office for National Statistics","year":"1996"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)04248-7"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427120-00004"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.935"},{"key":"e_1_2_1_18_2","unstructured":"British National Formulary.The British National Formulary 49 Online 2004 http:\/\/www.bnf.org (December2004)."},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2125.1998.00701.x","article-title":"Use of the UK General Practice Research Database for pharmacoepidemiology","volume":"45","author":"Garcia\u2010Rodriquez LA","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_20_2","first-page":"23","article-title":"Pregnancy labeling","author":"Food and Drug Administration","year":"1979","journal-title":"FDA Drug Bull"},{"key":"e_1_2_1_21_2","first-page":"37434","article-title":"FDA categories for drug use in pregnancy","volume":"44","author":"Food and Drug Administration","year":"1980","journal-title":"Fed Regist"},{"key":"e_1_2_1_22_2","first-page":"123","article-title":"Asthma during pregnancy: interrelationships and management","volume":"68","author":"Schatz M","year":"1992","journal-title":"Ann Allergy"},{"key":"e_1_2_1_23_2","unstructured":"LarimoreWL.Medications used in pregnancy and lactation. 1st ed.Medscape 1998 http:\/\/www.medscape.com(December1999)."},{"key":"e_1_2_1_24_2","volume-title":"Classification of medical products for use during pregnancy and lactation: The Swedish system","author":"FASS","year":"1993"},{"key":"e_1_2_1_25_2","volume-title":"Medicines in Pregnancy Working Party: Australian categorisation of drugs","author":"Australian Drug Evaluation Committee","year":"1989"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2004.04.022"},{"key":"e_1_2_1_27_2","first-page":"CD003511","article-title":"Progestogen for preventing miscarriage","volume":"4","author":"Oates\u2010Whitehead RM","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200023030-00006"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.04.025"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3016.2003.00542.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0412.1999.780805.x"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03209-8"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2005.14.401"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1269","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T19:32:10Z","timestamp":1700076730000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,12]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1002\/pds.1269"],"URL":"https:\/\/doi.org\/10.1002\/pds.1269","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,12]]}}}